IPOsBy The Online Investor Staff, updated Tue., Aug. 14, 10:50 PM
|This Slide: #1 of 15|
Slide #1. Aridis Pharmaceuticals, Inc. — Initial Public Offering
Aridis Pharmaceuticals, Inc.
Price Per Share:
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections, today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aridis. In addition, Aridis has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Aridis. The shares are expected to begin trading on the Nasdaq Capital Market on August 14, 2018 under the symbol "ARDS."